Prosecution Insights
Last updated: May 29, 2026

Celularity Inc.

6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready

Portfolio Summary

6
Total Pending OAs
3
Non-Final OAs
2
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
1
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 7 days (1)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (17%)
5
Medium (83%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only1 (17%)
§103 only3 (50%)
§102 only2 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
VAN BUREN, LAUREN K 1 38.9% +57.3%
TAKENAKA, RISA 1 15.4% +100.0%
TRAN, KHOA NHAT 1 35.4% +66.3%
BARRON, SEAN C 1 53.5% +30.9%
TIWARI, VYOMA SHUBHAM 1 30.2% +46.7%
KRCHA, MATTHEW D 1 65.9% +35.7%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18048291 ENHANCED PLACENTAL STEM CELLS AND USES THEREOF TAKENAKA, RISA 60d overdue
17309451 PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF TIWARI, VYOMA SHUBHAM 20d

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
17998199 PLACENTA-DERIVED ADHERENT (PDA) STEM CELL FOR THE TREATMENT OF ADULTS WITH SARS-COV-2 RELATED ACUTE RESPIRATORY FAILURE AND ARDS (COVID-19) VAN BUREN, LAUREN K 210d overdue
17630079 POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CD38 CHIMERIC ANTIGEN RECEPTOR TRAN, KHOA NHAT 155d overdue
17302353 DEVICES AND METHODS FOR THAWING BIOLOGICAL MATERIAL KRCHA, MATTHEW D 124d overdue
18048291 ENHANCED PLACENTAL STEM CELLS AND USES THEREOF TAKENAKA, RISA 60d overdue
17619242 POPULATIONS OF NATURAL KILLER CELLS FOR TREATING CANCERS BARRON, SEAN C 5d
17309451 PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF TIWARI, VYOMA SHUBHAM 20d

Top Art Units

Art UnitApps
1632 2
1638 1
1653 1
1634 1
1796 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17998199 PLACENTA-DERIVED ADHERENT (PDA) STEM CELL FOR THE TREATMENT OF ADULTS WITH SARS-COV-2 RELATED ACUTE RESPIRATORY FAILURE AND ARDS (COVID-19) VAN BUREN, LAUREN K 1638 §102 Non-Final OA 210d overdue Pending Nov 08, 2022
18048291 ENHANCED PLACENTAL STEM CELLS AND USES THEREOF TAKENAKA, RISA 1632 §103 Final Rejection 60d overdue Pending Oct 20, 2022
17630079 POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CD38 CHIMERIC ANTIGEN RECEPTOR TRAN, KHOA NHAT 1632 §103 Non-Final OA 155d overdue Pending Jan 25, 2022
17619242 POPULATIONS OF NATURAL KILLER CELLS FOR TREATING CANCERS BARRON, SEAN C 1653 §103 Non-Final OA 5d Pending Dec 14, 2021
17309451 PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF TIWARI, VYOMA SHUBHAM 1634 §101 Non-Final OA 20d Pending May 27, 2021
17302353 DEVICES AND METHODS FOR THAWING BIOLOGICAL MATERIAL KRCHA, MATTHEW D 1796 §102 Final Rejection 124d overdue Pending Apr 30, 2021

Managing Celularity Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month